{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:29:19Z","timestamp":1788262159573,"version":"build-2803163510"},"reference-count":31,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/13696998.2025.2506265","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T05:18:57Z","timestamp":1747113537000},"page":"743-752","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Non-optimal treatment with first tyrosine kinase inhibitor and associated economic burden in chronic myeloid leukemia"],"prefix":"10.1080","volume":"28","author":[{"given":"Vamsi","family":"Kota","sequence":"first","affiliation":[{"name":"Georgia Cancer Center at Wellstar MCG Health","place":["Augusta, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wei","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation","place":["East Hanover, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Yang","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation","place":["East Hanover, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5219-2612","authenticated-orcid":false,"given":"Hela","family":"Romdhani","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc","place":["Montr\u00e9al, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick","family":"Latremouille-Viau","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc","place":["Montr\u00e9al, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Gu\u00e9rin","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc","place":["Montr\u00e9al, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejal","family":"Jadhav","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation","place":["East Hanover, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27443"},{"key":"e_1_3_6_3_1","unstructured":"Bristol-Myers Squibb Company. SPRYCEL\u00ae (dasatinib) Prescribing Information Princeton NJ; 2023. Available from: https:\/\/packageinserts.bms.com\/pi\/pi_sprycel.pdf."},{"key":"e_1_3_6_4_1","unstructured":"Novartis Pharmaceuticals Corporation. TASIGNA\u00ae (nilotinib) Prescribing Information East Hanover NJ; 2021. Available from: https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/tasigna.pdf."},{"key":"e_1_3_6_5_1","unstructured":"Novartis Pharmaceuticals Corporation. GLEEVEC\u00ae (imatinib mesylate) Prescribing Information East Hanover NJ; 2022. Available from: https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/gleevec_tabs.pdf."},{"key":"e_1_3_6_6_1","unstructured":"Pfizer Inc. BOSULIF\u00ae. (bosutinib) Prescribing Information New York NY; 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/203341s025lbl.pdf."},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103580"},{"key":"e_1_3_6_8_1","unstructured":"Novartis Pharmaceuticals Corporation. SCEMBLIX\u00ae (asciminib) Prescribing Information East Hanover NJ; 2024. Available from: https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/scemblix.pdf."},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400858"},{"key":"e_1_3_6_10_1","unstructured":"ARIAD Pharmaceuticals Inc. ICLUSIG\u00ae (ponatinib) Prescribing Information Cambridge MA; 2024. Available from: https:\/\/www.iclusig.com\/sites\/default\/files\/2023-02\/iclusig-prescribing-information.pdf."},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13524"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25306"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-023-01329-9"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.36469\/001c.36975"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S29132"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_3_6_17_1","unstructured":"Bristol-Myers Squibb Company. FDA Approves SPRYCEL\u00ae (dasatinib) as Treatment for Adult Patients with Newly Diagnosed Ph\u2009+\u2009Chronic Myeloid Leukemia in Chronic Phase; 2010 [cited 2025 March 18]. Available from: https:\/\/news.bms.com\/news\/details\/2010\/FDA-Approves-SPRYCEL-dasatinib-as-Treatment-for-Adult-Patients-with-Newly-Diagnosed-Ph-Chronic-Myeloid-Leukemia-in-Chronic-Phase\/default.aspx."},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.10.61"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.7162"},{"key":"e_1_3_6_22_1","unstructured":"Pfizer Inc. U.S. FDA Approves Pfizer\u2019s BOSULIF\u00ae (bosutinib) for the Treatment of Patients with Newly-Diagnosed Ph\u2009+\u2009Chronic Myelogenous Leukemia (CML) 2017; [cited 2025 March 18]. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/u_s_fda_approves_pfizer_s_bosulif_bosutinib_for_the_treatment_of_patients_with_newly_diagnosed_ph_chronic_myelogenous_leukemia_cml."},{"key":"e_1_3_6_23_1","unstructured":"National Cancer Institute (NCI). NCI Comorbidity Index Overview 2024. [updated April 19 2024; cited 2024 September 6]. Available from: https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/considerations\/comorbidity.html."},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200725060-00004"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.104"},{"key":"e_1_3_6_26_1","unstructured":"U.S. Bureau of Labor Statistics. Measuring Price Change in the CPI: medical care 2023. Available from: https:\/\/www.bls.gov\/cpi\/factsheets\/medical-care.htm."},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217697484"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26689"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2021.106674"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1088654"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1120189"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.07.647"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2025.2506265","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:44:42Z","timestamp":1766400282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2025.2506265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/13696998.2025.2506265"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2025.2506265","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-02-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}